Genmab reports positive Epkinly trial results in DLBCL, expanding addressable market
Genmab A/S (GMAB) recently announced positive trial results for Epkinly in DLBCL, a type of non-Hodgkin lymphoma. This news puts the spotlight on whether the stock's current valuation fully reflects the potential commercial upside of this therapeutic advance.
The story
Genmab A/S (GMAB) reported positive results from its clinical trial for Epkinly (epcoritamab) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This is a significant development for the company, as Epkinly is a bispecific antibody developed in collaboration with AbbVie and is already approved for other indications.
The positive trial results could expand Epkinly's addressable market and solidify its position in the competitive oncology landscape. The drug's efficacy in DLBCL, a challenging cancer to treat, suggests a strong commercial opportunity.
Now, the market is evaluating whether GMAB's stock price, which currently reflects a company with $21.5B in revenue and 30.7% YoY growth, has fully priced in the potential sales boost and improved outlook from this expanded indication. The question is whether the market has adequately discounted the future revenue streams and profit margins (currently 36.4% net) that Epkinly could generate in this new segment.
Traders will be watching for analyst updates and management commentary on the regulatory path and commercialization strategy for Epkinly in DLBCL. The stock's performance will likely hinge on how quickly and effectively Genmab can translate these positive trial results into market share and revenue growth, especially considering its current P/E multiple relative to peers and growth prospects.
Our read · Wed, Jul 8
The market is weighing whether Genmab's (GMAB) valuation accurately reflects the upside potential from the positive Epkinly DLBCL trial results.
Why. Positive trial results for Epkinly in DLBCL represent a material expansion of the drug's market potential for Genmab. With $21.5B in revenue and 30.7% YoY growth already, this new indication could drive further top-line expansion and margin improvement given the 36.4% net margin. The stock appears undervalued if the market hasn't fully priced in this additional revenue stream.
Both cases
What could change this view: Regulatory hurdles or slower-than-expected commercial uptake of Epkinly in the DLBCL indication could limit upside. Competitive pressures in the oncology space are also a factor.
Who reported it · 1
Keep reading
Latest on the Wire
Trump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultContinue on the Wire →Latest on the Wire
Anthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeBeijing plans to bar young red-chip firms from overseas listingsGerman producer prices jump 8.1% in October as industrial inflation acceleratesContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by Yahoo Finance as Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →